ENTPD1 and neoplasm: Furthermore, dual-target adenosine-axis strategies—such as CD39/CD73 bispecific antibodies and multitarget metabolic inhibitors—aim to overcome compensatory enzymatic redundancy and more effectively suppress adenosine production within the tumor microenvironment (TME) (3, 7, 55).